×

RNS Number : 8336F

Shearwater Group PLC

24 March 2022

 

24 March 2022

RNS Reach

Shearwater Group PLC

("Shearwater", or the "Group")

Contract Win

Brookcourt Solutions secures new contract with leading telecommunications and media company

 

Shearwater Group plc, the organisational resilience group that provides cybersecurity, professional advisory and managed security services, announces that its group company, Brookcourt Solutions, has secured a new contract to the value of   c.£620,000   with a leading   telecommunications and media company. The contract contributes to the Group's current full year expectations.

 

The   solution is critical to help enable forensic monitoring of the organisation's new 5G network, allowing optimal performance to be achieved.

 

Phil Higgins, Group Chief Executive Officer of Shearwater, commented:

 

"We are delighted to win this new solution deal. Being able to supply an industry leading customer with value-adding solutions and services that contribute to streamlining their performance is a great achievement. This type of contract demonstrates that we are achieving the vision that we set out for ourselves as a Group: to be provider of choice delivering next generation technology, professional advisory and cyber security services and solutions."

 

Enquiries:
 

Shearwater Group plc David Williams Phil Higgins	www.shearwatergroup.com c/o Alma PR
Cenkos Securities plc – NOMAD and Joint Broker Ben Jeynes / Max Gould – Corporate Finance Alex Pollen / Michael Johnson – Sales	+44 (0) 20 7397 8900
Berenberg – Joint Broker  Matthew Armitt / Mark Whitmore	+44 (0) 20 3207 7800
Alma PR Susie Hudson / Caroline Forde / Joe Pederzolli	[email protected]  +44 (0) 20 3405 0205

 

This is an RNS Reach announcement and the information contained is not considered to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

About Shearwater Group plc

 

Shearwater Group plc is an award-winning group providing cyber security, managed security and professional advisory solutions to help create a safer online environment for organisations and their end users.
 

The Group's differentiated full service offering spans identity and access management and data security, cybersecurity solutions and managed security services, and security governance, risk and compliance. Its growth strategy is focused on building a scalable group that caters to the entire spectrum of cyber security and managed security needs, through a focused buy and build approach. The Group is headquartered in the UK, serving customers across the globe across a broad spectrum of industries.
 

Shearwater shares are listed on the London Stock Exchange's AIM under the ticker "SWG".  For more information, please visit www.shearwatergroup.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABKNBQDBKBPNB

Close

×

RNS Number : 5010F

Trakm8 Holdings PLC

22 March 2022

 

  22 March 2022

 

 

 Trakm8 Holdings plc

('Trakm8' or the 'Company')

 

 

Contract Award

Trakm8 Holdings plc (AIM: TRAK), the global telematics and data insight provider is pleased to announce that it has been awarded a contract with Adiona Technologies to provide data and devices for Adiona's insurance propositions. The partnership will also see Trakm8 and Adiona working alongside Duck Creek Technologies and World Programming.

Initial analysis of the Trakm8 journey data,  confirms the level of detail and real-time frequency  will support Adiona's  4 core pillars of;  Pricing and Selection, Risk Pool Management, Crash and Claim and Customer Engagement.

This contract is expected to commence writing insurance policies in Autumn 2022.

John Watkins, Executive Chairman, commented: "We are delighted to be working with Adiona as they launch their highly innovative AI based telematics insurance products. Adiona aim to disrupt the insurance market with their approach to telematics based solutions with a customer centric focus being a key driver."

Paul Harvey, CEO of Adiona Technologies said "We have already experienced Trakm8's agile and responsive support in preparing early prototypes and look forward to creating exciting solutions together."

– Ends –

 

For further information:

Trakm8 Holdings plc
John Watkins, Executive Chairman	Tel: +44 (0) 167 543 4200
Jon Edwards, CFO	www.trakm8.com
Arden Partners plc  (Nominated Adviser & Broker)	Tel: +44 (0) 20 7614 5900
Paul Shackleton, Corporate Finance Simon Johnson, Corporate Broking	www.arden-partners.com

 

About Trakm8

 

Trakm8 is a UK based technology leader in fleet management, insurance telematics, connected car, and optimisation. Through IP owned technology, the Group uses AI data analytics collected from its installed base of telematics units to fine tune the algorithms that are used to produce its' solutions; these monitor driver behaviour, identify crash events and monitor vehicle health to provide actionable insights to continuously improve the security and operational efficiency of both company fleets and private drivers.

 

The Group's product portfolio includes the latest data analytics and reporting portal (Trakm8 Insight), integrated telematics/cameras/optimisation, self-installed telematics units and one of the widest ranges of installed telematics devices. Trakm8 has over 255,000 connections.

 

Headquartered in Coleshill near Birmingham alongside its manufacturing facility, the Group supplies to the Fleet, Optimisation, Insurance and Automotive sectors to many well-known customers in the UK and internationally including the AA, Saint Gobain, EON, Iceland Foods, Parts Alliance, Direct Line Group, ByMiles and Ingenie.

 

Trakm8 has been listed on the AIM market of the London Stock Exchange since 2005. Trakm8 is also recognised with the LSE Green Economy Mark.

 

www.trakm8.com / @Trakm8

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASEEFMFEESEFD

Close

×

RNS Number : 4871F

Genedrive PLC

21 March 2022

 

 

genedrive plc

("genedrive" or the "Company")

 

PALOH study results published in JAMA Pediatrics

Publication confirms Genedrive® MT-RNR1 test's role in avoiding antibiotic related hearing loss in infants

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Pharmacogenetics to Avoid Loss of Hearing ("PALOH") trial, conducted at Manchester and Liverpool Hospitals to assess the implementation of the Genedrive® MT-RNR1 ID kit, has now been published in the Journal of the American Medical Association for Pediatrics ("JAMA Pediatrics"), which is the top ranked medical journal in pediatric medicine.

 

The accompanying editorial describes the application of the Genedrive® MT-RNR1 ID kit testing approach as "entering a new era", and "an important step" in the management of neonatal sepsis. The editorial also observes that identification of the m.1555A>G genetic variant can be performed in the acute setting without disrupting standards of care and that based on a population frequency of the variant and the use of antibiotics in more than seven million neonates each year globally, adoption of a MT-RNR1 point of care test would potentially avoid antibiotic induced hearing loss in thousands annually.

 

The PALOH study represented the world's first trial of a genetic Point of Care Test (POCT) designed to alter patient management in an acute, time-sensitive setting. The Genedrive® MT-RNR1 assay was used to screen for a genetic variant called m.1555A>G. If a baby carrying the gene variant is given the antibiotic gentamicin, a common treatment for bacterial infections, it can cause lifelong deafness.

 

A total of 751 neonates were recruited to the PALOH study throughout 2020. Three babies with the m.1555A>G variant were identified, all of whom avoided aminoglycoside antibiotics and therefore avoided profound hearing loss. The assay had a real-world analytical sensitivity of 100%, a specificity of 99.2% and an accuracy of 99.2%.  The mean time to antibiotics was equivalent to previous practice, indicating that the test can be introduced into routine practice. 

 

The study design of this trial allowed improvements to the system based on study data and clinical feedback, leading to a greatly improved system for commercialisation and clinical implementation. Throughout the trial, the MT-RNR1 hardware platform (Genedrive®) was updated to improve user efficiency (proportion of tests returning valid results) and accuracy. Repeated testing of samples where testing had previously failed demonstrated an improved performance rate of 94.3% when performed in the intended-use clinical setting and 100% when performed in a laboratory setting.

 

David Budd, CEO of genedrive plc, said: "The PALOH study demonstrates the ease of use and capability of the Genedrive® technology to deliver rapid genetic information in a very time sensitive acute care situation, a diagnostic advancement that has not been demonstrated previously with other commercial platforms. The conclusions in JAMA Pediatrics validate our intent in this market – there are millions of neonates exposed to antibiotics annually and our test could potentially prevent thousands going deaf each year. The PALOH study is a seminal document to support our commercial efforts going forwards."

 

The JAMA Pediatrics paper, entitled "Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care" was authored by Dr. John McDermott et al, and is printed in the 21st March 2022 edition of the Journal. The paper can be viewed here: https://tinyurl.com/kvusm8ts  

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel
finnCap (Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc ( http://www.genedriveplc.com )  genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and a high throughput SARS-CoV-2 assay.  The Company recently released point of care test for Covid-19.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCUAAVRUSUOUAR

Close

×

RNS Number : 0599F

Shearwater Group PLC

17 March 2022

 

17 March 2022

RNS Reach

Shearwater Group PLC

("Shearwater", or the "Group")

Contract Win

Brookcourt Solutions secures $4.1 million contract with a global financial organisation

 

Shearwater Group plc (AIM: SWG), the organisational resilience group that provides cybersecurity, advisory and managed security services, is pleased to announce that its group company, Brookcourt Solutions, has secured a significant three-year advanced endpoint cyber defence solution contract with a global financial organisation, totalling $4.1 million. The contract contributes to the Group's current full year expectations.

 

Under the terms of this contract, Brookcourt Solutions will be responsible for deploying one of its technology partners' cutting-edge endpoint security software solutions across the breadth of the financial organisation's operations. This solution will improve the resilience of the organisation's digital estate.

 

Phil Higgins, Group Chief Executive Officer of Shearwater, commented:

 

"This is an outstanding contract win for Brookcourt Solutions, demonstrating our deep understanding of best-in-class technologies and the strong partner portfolio that we have on offer for our customers. Being trusted to efficiently deploy cutting-edge, robust, effective and cost efficient cyber security solutions to global financial organisations of this calibre is something that we are very proud of."

 

Enquiries:
 

Shearwater Group plc David Williams Phil Higgins	www.shearwatergroup.com c/o Alma PR
Cenkos Securities plc – NOMAD and Joint Broker Ben Jeynes / Max Gould – Corporate Finance Julian Morse / Michael Johnson – Sales	+44 (0) 20 7397 8900
Berenberg – Joint Broker  Matthew Armitt / Mark Whitmore	+44 (0) 20 3207 7800
Alma PR Susie Hudson / Caroline Forde / Joe Pederzolli	[email protected]  +44 (0) 20 3405 0205

 

This is an RNS Reach announcement and the information contained is not considered to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

About Shearwater Group plc

 

Shearwater Group plc is an award-winning group providing cyber security, managed security and professional advisory solutions to help create a safer online environment for organisations and their end users.
 

The Group's differentiated full service offering spans identity and access management and data security, cybersecurity solutions and managed security services, and security governance, risk and compliance. Its growth strategy is focused on building a scalable group that caters to the entire spectrum of cyber security and managed security needs, through a focused buy and build approach. The Group is headquartered in the UK, serving customers across the globe across a broad spectrum of industries.
 

Shearwater shares are listed on the London Stock Exchange's AIM under the ticker "SWG".  For more information, please visit www.shearwatergroup.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABKABDBBKBOND

Close

×

Getmapping is a leading provider of cutting-edge geospatial data and solutions in the UK, with over 25 years of expertise in capturing and delivering high-resolution aerial imagery, LiDAR, mobile mapping, and web-based streaming services.

Further information can be found on the Company’s website: https://www.getmapping.co.uk/

Close

×

RNS Number : 7780D

Vela Technologies PLC

07 March 2022

 

7 March 2022

Vela Technologies plc

("Vela" or "the Company")

Update re. St George Street Capital Limited COVID-19 trial

 

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made by St George Street Capital ("SGSC") which provides an update on the positive outcome of the ARCADIA COVID-19 therapy trial.

Under an agreement entered into in August 2019, SGSC acquired the right to develop and commercialise two assets from a major global pharmaceutical company, one of which includes the licence to a drug that could be beneficial to diabetic patients suffering with COVID-19 (the "Asset"). Details of Vela's economic interest in the potential commercialisation of the Asset, the Asset and the ARCADIA trial were included in the announcement published by Vela on 20 October 2020.

 

James Normand, Director of Vela, commented:

"This update from SGSC indicates that the promise shown by earlier test results (which we have reported on previously) is being maintained.  We are pleased that the latest analysis of the results of the study of the application of the AZD1656 treatment is sufficiently encouraging to result in active engagement with potential commercial partners; and thus to vindicate our decision to invest.  We remain confident that the AZD1656 treatment has the potential to show a healthy return for SGSC and therefore for Vela."

 

Full details of the joint press release issued today by SGSC and Excalibur Medicines Ltd ("EML"), a biotechnology investment company, is extracted below. The Asset is referred to in the press release below as AZD1656:

 

Further analysis of data from the ARCADIA clinical study confirms that the addition of AZD1656 treatment to standard care resulted in fewer deaths and earlier hospital discharge in COVID-19 patients than did placebo treatment.

The ARCADIA Phase II multi-centre study was undertaken in over 150 diabetic patients hospitalised due to moderate to severe COVID-19 infection. Patients received either AZD1656 or placebo daily for up to 21 days in addition to standard care and antidiabetic medications. To be clear, all patients in the trial received standard of care treatment (over 70% in both groups received dexamethasone) with those in the drug group receiving AZD1656 in addition. No deaths occurred in those receiving AZD1656 in the first week of treatment, whereas six deaths occurred in the placebo group. All-cause mortality rates within 28 days of admission favoured the AZD1656 patients, with only four deaths occurring, versus nine deaths in the placebo group.

Thirty patients in the AZD1656 group (38%) were discharged from hospital within seven days of admission, but only 18 patients (25%) receiving placebo treatment. AZD1656 treatment was shown to be safe and well-tolerated.

In addition to the clinical benefit observed in this high-risk patient group, the immunological data gathered from the trial strongly supports SGSC's rationale for the ARCADIA study by confirming that AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of COVID-19 infection, while enhancing the virus-specific immune response.

Thus far, only a small number of repurposed or repositioned drugs have demonstrated benefits in treating COVID-19 infection in early clinical study1. SGSC believes that AZD1656 has the potential to become a valuable addition to the very small number of available COVID-19 drug treatments, offering a safer and more effective alternative to immunomodulatory treatments such as dexamethasone and other steroids, infused anti-cytokines (such as tocilizumab) and Janus kinase inhibitors2.

AZD1656 has an important advantage over small molecule and antibody antiviral agents in that due to its immodulatory effect, efficacy is unlikely to be compromised in treating disease caused by new coronavirus variants. The highly infectious Omicron variant appears to be associated with milder disease symptoms and lower hospitalisation rates, but we may not be so fortunate with future variants. "Variant agnostic", readily stockpiled, transported and easily administered treatments such as AZD1656 are essential for future pandemic preparedness.

SGSC is actively engaged in commercial discussions with appropriate global and regional pharmaceutical companies, with the objective of outright sale, partnership in future development or securing funding for the additional clinical studies necessary to get this to market. Ideally AZD1656 would be evaluated in broader non-diabetic patient populations, both hospitalised patients and those at higher risk of hospitalisation due to underlying health conditions. Despite the unknowns around the evolution of the pandemic, SGSC believes that AZD1656 has the potential to generate significant long-term revenue.

The COVID-19 pandemic has been truly global, and SGSC believes that AZD1656 could be particularly valuable in countries where limited hospital resources, low vaccine uptake and a high prevalence of vulnerable individuals have conspired to push up hospitalisation and death rates.

About AZD1656

AZD1656 was originally developed by AstraZeneca as a diabetes treatment and has an extensive record of safety in clinical studies involving more than one thousand subjects.  Preclinical data suggested a likely immune mode of action, leading SGSC to secure a licence to the agent as a therapy for inflammatory conditions.

In addition to the ARCADIA study supported by EML, the Mubadala Sovereign Wealth Fund, Chlodwig Enterprises and UKRI / Innovate UK, SGSC has actively built on the scope of AZD1656 through patent filing (COVID-19 combination treatment) and intends to exploit the beneficial immunomodulatory effect in immune dysfunction applications.

 

[1] COVID-19 early treatment: real-time analysis of 1,489 studies. https://c19early.com . Accessed 3rd Match 2022

[2] NIH Covid-19 Treatment Guidelines. Table 4f. Characteristics of Immunomodulators. https://tinyurl.com/3jbeucyh   Accessed 3rd March 2022

 

 

For further information, please contact:

Vela Technologies plc Brent Fitzpatrick, Non-Executive Chairman James Normand, Executive Director	Tel: +44 (0) 7421 728875
Allenby Capital Limited    (Nominated Adviser and Joint Broker)	Tel: +44 (0) 20 3328 5656
Nick Athanas/Piers Shimwell
Peterhouse Capital Limited    (Joint Broker)	Tel: +44 (0) 20 7469 0930
Lucy Williams / Duncan Vasey / Eran Zucker

 

About Vela Technologies 

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDMZGGFGVFGZZZ

Close

×

RNS Number : 1267D

FD Technologies PLC

01 March 2022

 

 

1 March 2022

FD Technologies plc

("FD Technologies" or the "Group")

 

KX Strategic Partnership Agreement with Microsoft

FD Technologies (AIM: FDP.L, Euronext Growth: FDP.I) announces that it has entered into a strategic partnership agreement with Microsoft to expand the reach of its KX Insights streaming data analytics platform as more organisations look to modernise their data infrastructure for real-time decision making. Firstly, KX Insights will be embedded natively on the Microsoft Azure platform as a first class service, with KX generating revenue based on consumption. Secondly, KX has agreed to work with Microsoft to target new applications and services that will accelerate innovation and growth for organisations in the financial services sector.

KX Insights on Azure

KX recognises there is a growing demand across industries for analytics solutions that can efficiently support client needs across both real-time streaming and historic data to enable real time business-critical decisions. KX Insights on Azure will enable customers to store and access their data using complex event processing, high-performance analytics and machine learning interfaces on one unified and easy-to-use platform. Tightly integrated within Microsoft's intelligent cloud ecosystem, the platform will work seamlessly with Microsoft services.

Designed for ease of deployment and commercial adoption, KX Insights on Azure represents a first-of-its kind native integration of a third-party streaming analytics solution on Azure. It will provide a quick and easy experience for customers to boost productivity, enabling significant cost reductions over legacy systems and will contribute towards an organisation's Azure consumption commitment. This aligns incentives for Azure and KX sales teams, enabling greater collaboration and engagement on sales and marketing initiatives with enterprise clients.

Joint development for capital markets

Additionally, KX intends to work with Microsoft to develop applications and services, leveraging KX's capabilities as the world's fastest time-series database as a core building block. This collaboration aims to help the capital markets ecosystem including exchanges, buy-side firms and sell-side institutions create high-value insights that facilitate real-time decision making.

Seamus Keating, CEO of FD Technologies, said: "This strategic partnership with Microsoft accelerates our mission to enable organisations to drive value from their real-time data assets. Enterprises will benefit from the unrivalled performance, scalability and security of KX Insights optimised for Microsoft Azure. In addition, we are excited to partner with Microsoft in developing technology solutions that address the demanding requirements of financial services organisations, particularly in capital markets where KX has a market-leading position. This is a landmark agreement for KX, with significant strategic benefits supporting our growth ambitions."

Bill Borden, Corporate Vice President of Worldwide Financial Services at Microsoft said: "KX Insights delivers industry leading, real-time streaming analytics solutions that transform how firms derive insights from market data.  Combining the full range of Microsoft's Intelligent Cloud capabilities with KX technology and expertise, we look forward to empowering our capital markets and financial services customers with new, compelling solutions for faster decision-making and innovation."

 

Enquiries

For further information please contact:

 

FD Technologies plc Seamus Keating, Chief Executive Officer Ryan Preston, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44 (0) 28 3025 2242 www.fdtechnologies.com
Investec Bank plc (Nominated Adviser and Broker) Andrew Pinder Carlton Nelson Virginia Bull	+44 (0) 20 7597 5970
Goodbody (Euronext Growth Adviser and Broker) David Kearney Don Harrington Finbarr Griffin	+353 1 667 0420
J.P. Morgan Cazenove (Broker) James A. Kelly Mose Adigun	+44 (0) 20 7742 4000
FTI Consulting (PR Adviser)	+44 (0) 20 3727 1000
Matt Dixon
Dwight Burden
Elena Kalinskaya

 

About FD Technologies

FD Technologies is a group of data-driven businesses that unlock the value of insight, hindsight and foresight to drive organisations forward. The Group comprises KX, the leading technology for real-time continuous intelligence; First Derivative, which provides technology-led services in capital markets; and MRP, the only enterprise-class, predictive Accounts Based Marketing solution. FD Technologies operates from 15 offices across Europe, North America and Asia Pacific, and employs more than 3,000 people worldwide.

For further information, please visit www.fdtechnologies.com and www.kx.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGREADDFEEEAEEA

Close

×

RNS Number : 9430C

Mears Group PLC

28 February 2022

 

 28 February 2022

Mears Group PLC

(the "Group" or the "Company")

 

Contract award – Residential Living Accommodation Project

 

 

Mears (LSE: MER), the leading provider of services to the UK Housing sector, is delighted to announce that it has been awarded the new Residential Living Accommodation Project ("RLAP") contract, providing a wide range of housing services to the Defence Infrastructure Organisation ("DIO"). The award is subject to contract and the successful completion of a standstill period.

 

The new contract is for a period of up to seven years and has an annual value in excess of £50 million. Under the contract, Mears will provide a wide range of accommodation and property services to service personnel and their families across the UK. Services include property search, selection and leasing, relocation services, tenancy management, responsive repairs and maintenance. The new contract is expected to commence in April 2022.

 

Mears has been successfully providing similar services since 2016 under the predecessor Substitute Service Accommodation contract, delivering a high level of service and operational delivery, which has contributed to this successful rebid.

 

 

David Miles, Chief Executive Officer of the Group, commented:

"We are proud of the role we play within the UK's Defence Infrastructure Organisation. With this contract award we can continue to provide the highest levels of service to these key personnel and their families and value for money to the DIO. Our operating and quality KPIs on this project have been excellent and this has clearly contributed to our successful rebid. Together with our contracts with the Home Office and the Ministry of Justice, today's successful award underlines that Mears is recognised as a trusted partner for specialist housing management services across Central Government departments. This award puts the Group in an excellent position for 2022 and beyond."

 

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014), as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

 

For further information, contact:

 

Mears Group PLC

David Miles, Chief Executive Officer
Andrew Smith, Finance Director
Alan Long, Executive Director
Joe Thompson, Investor Relations	Tel: +44(0)7980 844 580
Novella Communications
Tim Robertson	Tel: +44 (0) 203 151 7008
Claire de Groot
www.mearsgroup.co.uk

 

About Mears

Mears currently employs around 5,500 people and provides services in every region of the UK. In partnership with our Housing clients, we maintain, repair and upgrade the homes of hundreds of thousands of people in communities from remote rural villages to large inner-city estates. Mears has extended its activities to provide broader housing solutions to solve the challenge posed by the lack of affordable housing and to provide accommodation and support for the most vulnerable.

We focus on long-term outcomes for people rather than short-term solutions and invest in innovations that have a positive impact on people's quality of life and on their communities' social, economic and environmental wellbeing. Our innovative approaches and market leading positions are intended to create value for our customers and the people they serve while also driving sustainable financial returns for our providers of capital, especially our shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTBCGDDIUDDGDR

Close

×

Neville Registrars is delighted to welcome Cizzle Biotechnology Holdings PLC as the newest addition to its list of client companies.

Cizzle Biotechnology is a cancer diagnostics spin-out from the University of York.

Further information can be found on the Company's website: https://cizzlebiotechnology.com/

Close

×

RNS Number : 2039C

Immotion Group PLC

21 February 2022

 

Immotion Group plc

("Immotion", the "Company" or the "Group")

 Shark Reef Aquarium Expansion and Contract Extension, and Trading Update

 

Shark Reef Aquarium Expansion and Contract Extension

Immotion, the UK-based immersive entertainment group, is pleased to announce an expansion of capacity and a contract extension at Shark Reef Aquarium, inside Mandalay Bay Resort & Casino, Las Vegas, currently the Group's largest installation.

This will see the theatre capacity increase to 48 seats from its current 36 seats, allowing greater customer throughput, especially at peak times. The current contract, which will also include the expanded capacity, will also be extended by a further 12 month period through to 31 January 2024. We envisage that the expanded theatre will be fully operational in March 2022, in time for USA Spring Break.

Capacity Expansion at Other Partner Sites

In addition to the expansion at Shark Reef Aquarium, capacity at another two of our strongest performing sites has been significantly expanded.  Our installation at Sea Life London has been increased from 8 to 14 seats and we have also doubled the capacity of our installation at Odysea Aquarium (Scottsdale, Arizona) from 6 to 12 seats. 

These expansions demonstrate the potential to make our installations a material generator of revenue for both the Group and its partners and to establish our installations as core integrated attractions in partners' venues.

 

Trading Update

Summary

Further to the trading update on 16 December 2021, the Company is pleased to confirm that unaudited H2 revenue was circa £6.6m, a 135% increase compared to unaudited revenue of £2.8m in H1 (H2 2020: £2.0m).

H2 operating cash inflow was strong, with year-end cash on hand of £1.1m, almost double the £0.6m at the half year.

Location Based Entertainment ("LBE") 

Trading in our core LBE division in the second half of 2021 has been very encouraging with unaudited revenue of £4.0m, a 74% increase compared to £2.3m in H1, and a 207% increase compared to £1.3m H2 2020.

We opened two new sites in H2 and now have a total of 49 sites (373 headsets), with 57 per cent. of headsets now located in the USA. We continue to see new interest in our 'Undersea Explorer' theatre style offering for aquariums and are now in advanced discussions with a number of major zoos regarding the first installations of our new 'Gorilla Trek' VR Theatre and we expect our first signings in the coming weeks. 

Home Based Entertainment ("HBE")

We sold circa 35,000 units of our Let's Explore Oceans product in 2021, generating unaudited revenue of £2.5m, a three-fold increase compared to £0.7m in 2020.

Whilst the sales growth was very encouraging, with the product selling out in the UK, both direct and via Amazon, and on Amazon in the USA, we were hit in the final six weeks of 2021 by very challenging logistics, which had a significant adverse impact on landed product costs. We also suffered with some stock not reaching its destination in time resulting in lost sales. The delayed stock, 5,000 units in total, will be sold throughout 2022.

The soft 'beta' launch of our Vodiac offering began late-December with invitations sent to the Let's Explore Oceans users.  We have seen over 4,350 downloads of the iOS and Android apps and over 1,250 premium VR video purchases so far. These data points have been used to further hone the headset offering which will go on sale this coming week. The product will be available online via Vodiac.com and Amazon, and through a number of new retail partners.  The blend of direct to consumer, Amazon and retail should allow us to gather sufficient data as to how to best scale this business.

Uvisan

Uvisan's total unaudited revenue for H2 was £0.4m (up from £0.1m in H1), demonstrating the value of our growing distributor and reseller network.  We now have 12 resellers and 3 distributors, located in the UK, Europe and the USA.  We are seeing growing demand for our UV sanitising cabinets.

As well as demand for our UV cabinets for sanitising a wide range of "touched" products, we see real opportunity in the enterprise, education and training XR headset and device market (virtual reality, augmented reality and mixed reality) which is set for huge growth in coming years.  Accordingly, we will focus on building a network of partners with deep roots into that sector.

Despite a number of early enquiries, we chose to delay the launch of Cleanroom in order to refine its proprietary safety and control features and we continue to believe that it has significant potential in healthcare, office and other sectors, in both new build and refurbishment projects. We are now ready to work with our growing partner network to commercialise this product.

Uvisan now has an order book of circa £0.3m and we are looking forward to a year which should see substantial growth versus 2021.

Martin Higginson, CEO, Immotion Group plc said:

"To see our core LBE business bounce back so quickly clearly demonstrates its robustness and growth potential.   We are absolutely delighted to be expanding capacity at a number of key sites, especially our largest installation at Shark Reef Aquarium, Mandalay Bay Resort & Casino which will now run through to at least January 2024.

"The launch of our new 'Gorilla Trek' VR theatre experience has been extremely well received and we look forward to signing up our first zoo partner in the coming weeks. This sector offers huge global roll out potential with many USA zoos boasting footfall well in excess of a million visitors per annum.

"Despite the logistical challenges, we sold circa 35,000 units of our Let's Explore Oceans product, as well as gaining a new distribution partner in Australia. Vodiac will carry forward the key learning so far in order to provide a broader product offering to a wider audience. We believe there is a real opportunity to democratise the home VR video market. Our offering of a VR headset, combined with original and curated VR content at a sub £30 price tag will, we believe, allow us to build an audience of scale.

"Our Uvisan products continued to sell well, with a growing roster of distribution partners, including in Australia and the USA.

"Overall, we feel we have made good progress across the company and are looking forward with renewed confidence."

 

Enquiries:

For further information please visit www.immotion.co.uk, or contact:

 

Immotion Group plc	Martin Higginson David Marks	[email protected]
WH Ireland Limited (Nomad and Joint Broker)	Adrian Hadden  Jessica Cave Darshan Patel Ben Good	Tel + 44 (0) 207 220 1666
Alvarium Capital Partners (Joint Broker)	Alex Davies	Tel: +44 (0) 207 195 1458

 

Shard Capital Partners LLP (Co-Broker)

Damon Heath Erik Woolgar

Tel: +44 (0) 20 7186 9900

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulaon (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TSTQBLFLLLLXBBQ

Close